QualityStocksNewsBreaks Archives - Page 20 of 1408

ThursdayJul 10, 2025 1:15 pm

QualityStocksNewsBreaks – Meta Platforms Inc. (NASDAQ: META) Snags Apple AI Lead With Over $200M Deal

Meta Platforms (NASDAQ: META) is reportedly preparing to invest approximately $14.8 billion for a 49% stake in Scale AI, a leading provider of data-labeling services critical to AI model training. As part of the deal, Scale AI’s CEO, Alexandr Wang, will join Meta to spearhead a new “superintelligence” lab alongside a 50‑person research team personally led by Mark Zuckerberg. The move comes in the wake of underperforming Llama 4 and delays to the “Behemoth” flagship AI model, making this Meta’s boldest strategic pivot in AI to date. On the regulatory front, U.S. antitrust authorities—particularly the FTC and DOJ—are scrutinizing even minority investments under…

ThursdayJul 10, 2025 9:30 am

QualityStocksNewsBreaks – ONAR Holding Corp. (OTCQB: ONAR) to Present on AI-Driven Commerce at GenAI Week Silicon Valley 2025

ONAR (OTCQB: ONAR), a marketing-technology company and agency network, announced that CEO Claude Zdanow will deliver a keynote at GenAI Week Silicon Valley 2025. His talk, “From SEO to LMO: How AI Language Models Are Rewriting the Rules of AI-Driven Digital Commerce,” is scheduled for July 14 from 12:00 to 12:20 p.m. PDT on the Align Stage. Zdanow will outline how Language Model Optimization (LMO) is replacing traditional SEO and share four key strategies for brands to succeed in the evolving AI-first commerce landscape. GenAI Week, taking place July 13–17 at the Santa Clara Convention Center, will host over 30,000…

ThursdayJul 10, 2025 9:10 am

QualityStocksNewsBreaks – Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) Completes Historic REVIVE Trial, Sets Stage for Long COVID Breakthrough and Market Expansion

Fifty 1 Labs (OTC: FITY), through its subsidiary Fifty1 AI Labs, LLC, announced the successful completion of the REVIVE Adaptive Platform Trial (NCT06128967), a groundbreaking Phase III study and the largest Long COVID trial to date. Conducted with global partners and top institutions including Stanford and Duke, the randomized, double-blind trial enrolled over 600 participants and demonstrated a clear treatment benefit using repurposed medicines. Powered by FITY’s proprietary AI platform, the trial sets a new standard in drug repurposing and personalized medicine, while supporting the company’s broader strategy to lead the $320.6 billion functional medicine market, pursue strategic acquisitions, and…

ThursdayJul 10, 2025 9:00 am

QualityStocksNewsBreaks – Fusion Fuel Green PLC (Nasdaq: HTOO) Announces 1-for-35 Reverse Share Split to Regain Nasdaq Compliance

Fusion Fuel Green (Nasdaq: HTOO) today announced a 1-for-35 reverse share split of its Class A Ordinary Shares, effective at market open on Monday, July 14, 2025. The split is intended to restore compliance with Nasdaq’s minimum bid price requirement. Following the split, the number of outstanding Class A shares will decrease from approximately 27.4 million to 783,376, with the new CUSIP number G3R25D 209. No fractional shares will be issued, and any resulting fractions will be rounded up. Shareholders are not required to take action, as changes will be automatically reflected in accounts. The authorized share capital will remain…

WednesdayJul 09, 2025 3:03 pm

QualityStocksNewsBreaks – Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Advances Portfolio in Walker Lane Hotspot

As Nevada’s Walker Lane becomes a prime target for mineral exploration, Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is strategically positioned to capitalize, owning and developing four high-potential exploration properties in the area. “With a vision to evolve into Nevada’s premier silver and gold producer, Lahontan has built a robust portfolio of assets across this geologically diverse and historically rich trend,” reads a recent article. “The company controls four properties in the heart of Walker Lane: Santa Fe, West Santa Fe, Moho and Redlich. The company’s flagship project, the Santa Fe Mine, is a 26.4 km2 past-producing, oxide-hosted gold-silver property. Between 1988 and 1995,…

WednesdayJul 09, 2025 1:52 pm

QualityStocksNewsBreaks – Adageis’ Platform Tackles Healthcare Complexities with AI

Adageis was featured in a recent article that discussed its powerful and patented AI-centric software solution. “Healthcare is a complicated place, and navigating the system is extremely difficult for patients,” Adageis’ CEO Shane Speirs was quoted as saying. “What Adageis does is provide a simple solution to healthcare organizations, ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. We offer a solution that meets everyone’s needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with.” To view the full article, visit https://ibn.fm/0qpNW About Adageis Adageis is a healthcare technology innovator focused…

WednesdayJul 09, 2025 9:20 am

QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Commissions Valuation to Advance Beacon Gold Mill Restart

LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) has engaged Bumigeme Inc. to conduct an independent valuation report of its fully owned Beacon Gold Mill in Val-d'Or, Québec. The report will assess replacement value and restart costs for the mill and tailings facility, which received over $20 million in upgrades in 2022. The valuation aims to support financing efforts and highlight the company’s potential to monetize production at the Beacon Mill, tied to the Swanson Gold Project. LaFleur Minerals is preparing for gold production and a Preliminary Economic Assessment while leveraging favorable market conditions, including J.P. Morgan’s forecast of $4,100…

WednesdayJul 09, 2025 9:00 am

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a shareholder update outlining key clinical and strategic milestones. President and CEO Dr. Christopher J. Schaber highlighted upcoming data readouts for lead candidates, including Phase 3 FLASH 2 results for HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma expected in 2H 2026, and multiple updates in 3Q and 4Q 2025 across psoriasis (SGX302) and Behçet’s Disease (SGX945). An investigator-initiated study also showed a 75% success rate at 18 weeks. The company projects HyBryte(TM) peak U.S. annual sales of over $90 million and global opportunities…

TuesdayJul 08, 2025 3:36 pm

QualityStocksNewsBreaks – Silvercorp Metals Inc.’s (NYSE American: SVM) (TSX: SVM) Growing Portfolio, Strong Balance Sheet Drive Investor Appeal

Silvercorp Metals (NYSE American: SVM) (TSX: SVM), a Canadian mining company producing silver, gold, lead, and zinc, delivered its strongest fourth-quarter performance to date. The company closed out fiscal 2025, ended March, with significant growth in both revenue and operating cash flow with results reflecting increased production volumes and stronger realized prices across the company’s key metals. “Income from mine operations in the quarter climbed to $26.1 million, up from $13.0 million in Q4 Fiscal 2024. Silvercorp also increased capital investments in its core operations, spending $9.9 million in China and $3.1 million on its El Domo project in Ecuador…

TuesdayJul 08, 2025 3:03 pm

QualityStocksNewsBreaks – Why HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. “HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection, but also unlocks future capabilities in ischemia detection, AI-assisted analysis, and longitudinal cardiac trend tracking,” reads a recent article. “As it approaches commercialization, HeartBeam is executing a multi-phase go-to-market strategy with initial U.S. rollout plans and a focus…

Site Search

Company Search

Category: QualityStocksNewsBreaks